- Oral presentation
- Open Access
T2 abnormalities in patients with hypertrophic cardiomyopathy characterized by cardiovascular magnetic resonance imaging- an indicator of myocardial injury as assessed by the high sensitive cardiac troponin T assay
© Lehrke et al; licensee BioMed Central Ltd. 2012
- Published: 1 February 2012
- Cardiovascular Magnetic Resonance
- Hypertrophic Cardiomyopathy
- Cardiovascular Magnetic Resonance Imaging
- Left Ventricular Segment
- Septal Wall Thickness
To test the hypothesis that myocardial hyper- intensities on T2 weighted imaging in patients with hypertrophic cardiomyopathy (HCM) reflect ongoing myocardial injury, the cardiac- specific biomarker troponin T was measured by a new highly sensitive assay (hs-cTnT). In 52 patients with HCM, the presence and extent of myocardial T2 abnormalities were associated with hs-cTnT levels. The number of LV segments with T2 hyper-intesity was the strongest independent predictor of hs-cTnT levels. This novel finding suggests that T2 imaging may aid in the identification of HCM patients with active and potentially progressive disease.
In a sub-group of patients with hypertrophic cardiomyopathy (HCM) abnormalities on T2 weighted imaging on cardiovascular magnetic resonance imaging (CMR) have been reported. The significance of this finding is still not clear, although it has been proposed to reflect ongoing myocardial injury. The loss of cardiomyocyte cell integrity leads to the release of troponins into the circulation. Recently, a highly sensitive cardiac troponin T assay (hs-cTnT) was introduced which allows the detection and quantification of very low serum levels of cTnT with a high diagnostic accuracy.
We therefore aimed to test the hypothesis that the presence and extent of myocardium with increased signal intensity on T2-weighted images in patients with HCM is associated with evidence of cardiomyocyte injury as assessed by the hs-cTnT assay.
The study cohort consists of 52 patients undergoing late gadolinium enhanced CMR (LGE-CMR) on a 1.5T clinical scanner (Philips Intera Achieva®) for characterization of hypertrophic cardiomyopathy in whom hs-cTnT was measured by the ELECSYS® assay (Roche Diagnostics). Left ventricular (LV) volumes and mass were derived from SSFP images. The presence of hyper-intense areas on T2 images was assessed in the modified LV AHA-16 segment model by two blinded observers. LGE was quantified in percent of LV mass.
Predictors of continuous hs-cTnT levels
95% CI of B
Age (per year)
Creatinin (per mg/dl)
LV-EF (per %)
LV-T2 (per segment)
LGE volume (per %)
LV-T2 (per segment)
The presence and the extent of myocardial T2 abnormalities in patients with HCM predict serum levels of hs-cTnT and thus seem to reflect ongoing myocardial damage. Whether this finding is associated with an increased risk for future adverse events needs to be examined in further studies.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.